GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » Degree of Financial Leverage

TELO (Telomir Pharmaceuticals) Degree of Financial Leverage : 13.77 (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Telomir Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2025 was 13.77. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Telomir Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

TELO's Degree of Financial Leverage is ranked worse than
98.34% of 1447 companies
in the Biotechnology industry
Industry Median: 0.95 vs TELO: 13.77

Telomir Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Telomir Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals Degree of Financial Leverage Chart

Telomir Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Degree of Financial Leverage
- 0.93 1.19 4.36

Telomir Pharmaceuticals Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.56 1.06 4.36 13.77

Competitive Comparison of Telomir Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Telomir Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telomir Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telomir Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Telomir Pharmaceuticals's Degree of Financial Leverage falls into.


;
;

Telomir Pharmaceuticals Degree of Financial Leverage Calculation

Telomir Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.42 (Mar. 2025) / -0.655 (Mar. 2024) - 1 )/( -12.526 (Mar. 2025) / -12.861 (Mar. 2024) - 1 )
=-0.3588/-0.026
=13.77***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Telomir Pharmaceuticals  (NAS:TELO) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Telomir Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Telomir Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
100 South East, 2nd Street, Suite 200, No.1009, Miami, FL, USA, 33131
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.

Telomir Pharmaceuticals Headlines

From GuruFocus